Impact News +++ BAIDU Aktie: JPMorgan sieht 61%-Wachstum bei Cloud - Kursziel deutlich erhöht (Aktiencheck) +++ BAIDU ADR Aktie +3,10%

PROMIS NEUROSCIENCES Aktie

>PROMIS NEURO Aktienkurs

0.302 EUR -18.4% (Tradegate)

Ask: 0.298 EUR / 5100 Stück

Bid: 0.29 EUR / 5200 Stück

Tagesumsatz: 10569 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

PROMIS NEURO Aktie über LYNX handeln

Intraday

1 Jahr

>PROMIS NEURO Performance

1 Woche: 0%

1 Monat: -6,7%

3 Monate: -25,2%

6 Monate: -23,2%

1 Jahr: -62,3%

laufendes Jahr: -59,3%

>PROMIS NEUROSCIENCES Aktie

Name:

PROMIS NEUROSCIENCES

Land:

Kanada

Sektor:

Gesundheit

ISIN/ Wkn:

CA74346M4065 / A3DM9Q

Symbol/ Ticker:

23J0 (Frankfurt) / PMN (NASDAQ)

Kürzel:

FRA:23J0, ETR:23J0, 23J0:GR, NASDAQ:PMN

Index:

Webseite:

https://www.promisneurosc..

Profil:

ProMIS Neurosciences Inc. is a biotechnology compa..
>Volltext..

Marktkapitalisierung:

17.84 Mio. EUR

Unternehmenswert:

4.68 Mio. EUR

Umsatz:

EBITDA:

-30.74 Mio. EUR

Nettogewinn:

-25.43 Mio. EUR

Gewinn je Aktie:

-0.65 EUR

Schulden:

Liquide Mittel:

13.37 Mio. EUR

Operativer Cashflow:

-23.76 Mio. EUR

Bargeldquote:

1.26

Umsatzwachstum:

Gewinnwachstum:

-4832.15%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

PROMIS NEUROSCIENCES, PROMIS NEURO

Letzte Datenerhebung:

24.11.25

>PROMIS NEURO Kennzahlen

Aktien/ Unternehmen:

Aktien: 32.69 Mio. St.

Frei handelbar: 64.11%

Leerverk. Aktien: 0.52%

Rückkaufquote: -103.54%

Mitarbeiter: 7

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 1166.15%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 2.5

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -127.41%

Eigenkaprendite: -355.8%

>PROMIS NEURO Peer Group

Es sind 182 Aktien bekannt.

>PROMIS NEURO Chart & Kurs - NASDAQ

>PROMIS NEURO News

24.11.25 - 15:24	ProMIS Neurosciences: Aktie bricht nach Ankündigung von Reverse Split ein (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

24.11.25 - 14:33	ProMIS Neurosciences to execute 1-for-25 reverse stock split (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

24.11.25 - 14:03

ProMIS Neurosciences Announces Reverse Stock Split (GlobeNewswire EN)

Cambridge, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that its board of directors has determined to effect a one-for-twenty-five reverse stock split of the Company's common shares, no par value per share (Common Shares)....

12.11.25 - 15:48	ProMIS Neurosciences GAAP EPS of -$0.24 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.11.25 - 13:06	ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights (GlobeNewswire EN)
	Phase 1b trial in Alzheimer's disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolledPMN310 continues to demonstrate a favorable safety profileOn track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026...

03.11.25 - 22:09

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire EN)

Cambridge, Massachusetts, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, and members of senior management will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim 2nd Annual Healthcare Innovation Conference on Monday, November 10th, 2025 in Boston, MA....

22.10.25 - 13:33	ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group (GlobeNewswire EN)
	Appointment reinforces ProMIS Neurosciences' strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer's program, PMN310...

06.10.25 - 19:01	Insiderhandel: Insider kauft Aktien von ProMIS Neurosciences im Wert von 14929 USD (Insiderkauf)
	Milbury, Max A. - Sonstiges / enge Beziehung - Tag der Transaktion: 2025-10-03...

04.09.25 - 23:06	ProMIS Neurosciences files to sell 28.23M common shares for holders (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.09.25 - 13:03	ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer′s Trial of PMN310 (GlobeNewswire EN)
	Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level);...

13.08.25 - 16:30	ProMIS Neurosciences GAAP EPS of -$0.29 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

28.07.25 - 13:03	ProMIS Neurosciences Announces Private Placement Financing (GlobeNewswire EN)
	$3 million private financing plus an additional $9 million of proceeds due to exercise of warrants, for gross proceeds of approximately $12.0 million $3 million private financing plus an additional $9 million of proceeds due to exercise of warrants, for gross proceeds of approximately $12.0 million...

22.07.25 - 13:36	ProMIS Neurosciences raises $3.2M through ATM offering, PIPE financing (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.07.25 - 13:03	ProMIS Neurosciences Announces Private Placement Financing (GlobeNewswire EN)
	$2.4 million private financing plus an additional $6.8 million of proceeds due to exercise of warrants and $0.8 million from a registered offering for gross proceeds of $9.2 million $2.4 million private financing plus an additional $6.8 million of proceeds due to exercise of warrants and $0.8 million from a registered offering for gross proceeds of $9.2 million...

12.05.25 - 19:42	ProMIS Neurosciences GAAP EPS of -$0.21 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.05.25 - 13:33	ProMIS Neurosciences Announces First Quarter 2025 Financial Results (GlobeNewswire EN)
	First Cohort Completed in PRECISE-AD Trial Evaluating PMN310 in Alzheimer's Disease ...

31.03.25 - 19:30	ProMIS Neurosciences GAAP EPS of $0.11 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.03.25 - 13:03	ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights (GlobeNewswire EN)
	Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer's Disease...

24.03.25 - 12:03	ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer′s Disease/Parkinson′s Disease 2025 International Conference (GlobeNewswire EN)
	Multiple datasets support continued development of ProMIS' antibody therapeutics and vaccines that selectively target toxic misfolded proteins to treat neurodegenerative diseases Multiple datasets support continued development of ProMIS' antibody therapeutics and vaccines that selectively target toxic misfolded proteins to treat neurodegenerative diseases...

13.03.25 - 12:03

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting (GlobeNewswire EN)

CAMBRIDGE, Massachusetts , March 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that the Company will present preclinical data on computationally-derived vaccines for neurodegenerative diseases at the American Academy of Neurology (AAN) Annual Meeting taking place from April 5-9, 2025 in San Diego....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Liebe kann alles, Geld besiegt alles, die Zeit zehrt alles auf, und der Tod endet alles. - Sprichwort Italien

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram